Here are six observations:
1. Duke is the only center in the state, and just one of 10 sites nationwide, participating in the VENUS clinical trial.
2. The trial will be used to evaluate the company’s investigational meniscus implant for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.
3. The VENUS study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. To be eligible, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago.
4. Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery.
5. The NUsurface Meniscus Implant from Active Implants is an investigational treatment for patients with persistent knee pain following medial meniscus surgery.
6. Active Implants is a medical device company that develops orthopedic implant solutions.
More articles on devices and implants:
Active Implants initiates 2nd NUsurface meniscus implant trial: 4 things to know
BONESUPPORT’s CERAMENT registry hits 230 cases: 5 notes
Episurf Medical’s μifidelity platform reaches 100 case milestone: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
